{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:52:23Z","timestamp":1791348743988,"version":"4.3.1"},"reference-count":220,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40265-022-01726-y","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T08:02:41Z","timestamp":1653984161000},"page":"865-887","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7360-417X","authenticated-orcid":false,"given":"Deepak","family":"Menon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5805-4883","authenticated-orcid":false,"given":"Vera","family":"Bril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"issue":"1","key":"1726_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):1\u201319.","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"1726_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1477-7525-8-129","volume":"11","author":"S Twork","year":"2010","unstructured":"Twork S, Wiesmeth S, Klewer J, P\u00f6hlau D, Kugler J. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes. 2010;11(8):129.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"1726_CR3","doi-asserted-by":"publisher","first-page":"e013278","DOI":"10.1136\/bmjopen-2016-013278","volume":"7","author":"Y Nagane","year":"2017","unstructured":"Nagane Y, Murai H, Imai T, Yamamoto D, Tsuda E, Minami N, et al. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open. 2017;7(2):e013278.","journal-title":"BMJ Open"},{"issue":"1","key":"1726_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.nmd.2015.10.009","volume":"26","author":"A Breiner","year":"2016","unstructured":"Breiner A, Widdifield J, Katzberg HD, Barnett C, Bril V, Tu K. Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscul Disord. 2016;26(1):41\u20136.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"1726_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010;10(1):46.","journal-title":"BMC Neurol"},{"key":"1726_CR6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis K, Tzartos SJ. Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics. Front Immunol. 2020;11:212.","journal-title":"Front Immunol"},{"issue":"1","key":"1726_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1055\/s-2004-829585","volume":"24","author":"BW Hughes","year":"2004","unstructured":"Hughes BW, Moro De Casillas ML, Kaminski HJ. Pathophysiology of myasthenia gravis. Semin Neurol. 2004;24(1):21\u201330.","journal-title":"Semin Neurol"},{"issue":"4","key":"1726_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40265-019-1065-0","volume":"79","author":"G Beecher","year":"2019","unstructured":"Beecher G, Putko BN, Wagner AN, Siddiqi ZA. Therapies directed against B-cells and downstream effectors in generalized autoimmune myasthenia gravis: current status. Drugs. 2019;79(4):353\u201364.","journal-title":"Drugs"},{"issue":"9","key":"1726_CR9","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.autrev.2013.03.003","volume":"12","author":"E T\u00fcz\u00fcn","year":"2013","unstructured":"T\u00fcz\u00fcn E, Christadoss P. Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun Rev. 2013;12(9):904\u201311.","journal-title":"Autoimmun Rev"},{"key":"1726_CR10","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s00415-015-7963-5","volume":"263","author":"S Binks","year":"2016","unstructured":"Binks S, Vincent A, Palace J. Myasthenia gravis: a clinical-immunological update. J Neurol. 2016;263:826\u201334.","journal-title":"J Neurol"},{"issue":"9","key":"1726_CR11","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","volume":"12","author":"A Marx","year":"2013","unstructured":"Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, Str\u00f6bel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev. 2013;12(9):875\u201384.","journal-title":"Autoimmun Rev"},{"key":"1726_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3389\/fneur.2020.00538","volume":"11","author":"D Menon","year":"2020","unstructured":"Menon D, Barnett C, Bril V. Novel treatments in myasthenia gravis. Front Neurol. 2020;11:538.","journal-title":"Front Neurol"},{"issue":"3","key":"1726_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/14728214.2021.1952982","volume":"26","author":"D Menon","year":"2021","unstructured":"Menon D, Urra Pincheira A, Bril V. Emerging drugs for the treatment of myasthenia gravis. Expert Opin Emerg Drugs. 2021;26(3):259\u201370.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"6","key":"1726_CR14","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mus.23330","volume":"45","author":"M Benatar","year":"2012","unstructured":"Benatar M, Sanders DB, Burns TM, Cutter GR, Guptill JT, Baggi F, et al. Recommendations for myasthenia gravis clinical trials. Muscle Nerve. 2012;45(6):909\u201317.","journal-title":"Muscle Nerve"},{"key":"1726_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.expneurol.2014.12.022","volume":"270","author":"AR Punga","year":"2015","unstructured":"Punga AR, Kaminski HJ, Richman DP, Benatar M. How clinical trials of myasthenia gravis can inform pre-clinical drug development. Exp Neurol. 2015;270:78\u201381.","journal-title":"Exp Neurol"},{"issue":"1","key":"1726_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16\u201323.","journal-title":"Neurology"},{"issue":"4","key":"1726_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mus.23944","volume":"49","author":"DB Sanders","year":"2014","unstructured":"Sanders DB, Burns TM, Cutter GR, Massey JM, Juel VC, Hobson-Webb L, et al. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? Muscle Nerve. 2014;49(4):483\u20136.","journal-title":"Muscle Nerve"},{"issue":"2","key":"1726_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ncl.2018.01.006","volume":"36","author":"C Barnett","year":"2018","unstructured":"Barnett C, Herbelin L, Dimachkie MM, Barohn RJ. Measuring clinical treatment response in myasthenia gravis. Neurol Clin. 2018;36(2):339\u201353.","journal-title":"Neurol Clin"},{"issue":"5779","key":"1726_CR19","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/S0140-6736(00)94294-6","volume":"223","author":"MB Walker","year":"1934","unstructured":"Walker MB. Treatment of myasthenia gravis with physostigmine. Lancet. 1934;223(5779):1200\u20131.","journal-title":"Lancet"},{"issue":"4","key":"1726_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"issue":"5","key":"1726_CR21","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/bjaceaccp\/mkh045","volume":"4","author":"VP Nair","year":"2004","unstructured":"Nair VP, Hunter JM. Anticholinesterases and anticholinergic drugs. Contin Educ Anaesth Crit Care Pain. 2004;4(5):164\u20138.","journal-title":"Contin Educ Anaesth Crit Care Pain"},{"issue":"3","key":"1726_CR22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2165\/00003088-198611030-00005","volume":"11","author":"S-M Aquilonius","year":"1986","unstructured":"Aquilonius S-M, Hartvig P. Clinical pharmacokinetics of cholinesterase inhibitors. Clin-Pharmacokinet. 1986;11(3):236\u201349.","journal-title":"Clin-Pharmacokinet."},{"issue":"2","key":"1726_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s004150050059","volume":"244","author":"R Beekman","year":"1997","unstructured":"Beekman R, Kuks JB, Oosterhuis HJ. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol. 1997;244(2):112\u20138.","journal-title":"J Neurol"},{"issue":"6","key":"1726_CR24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/BF00315656","volume":"237","author":"R Mantegazza","year":"1990","unstructured":"Mantegazza R, Beghi E, Pareyson D, Antozzi C, Peluchetti D, Sghirlanzoni A, et al. A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol. 1990;237(6):339\u201344.","journal-title":"J Neurol"},{"issue":"10","key":"1726_CR25","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2165\/11593300-000000000-00000","volume":"31","author":"L Maggi","year":"2011","unstructured":"Maggi L, Mantegazza R. Treatment of myasthenia gravis: focus on pyridostigmine. Clin Drug Investig. 2011;31(10):691\u2013701.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"1726_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/mus.20935","volume":"37","author":"AR Punga","year":"2008","unstructured":"Punga AR, Sawada M, St\u00e5lberg EV. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. Muscle Nerve. 2008;37(3):300\u20137.","journal-title":"Muscle Nerve"},{"issue":"10","key":"1726_CR27","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1093\/brain\/awg223","volume":"126","author":"A Evoli","year":"2003","unstructured":"Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126(10):2304\u201311.","journal-title":"Brain"},{"issue":"Pt 10","key":"1726_CR28","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1113\/jphysiol.2013.254599","volume":"591","author":"AG Engel","year":"2013","unstructured":"Engel AG. Why does acetylcholine exacerbate myasthenia caused by anti-MuSK antibodies? J Physiol. 2013;591(Pt 10):2377.","journal-title":"J Physiol"},{"issue":"5","key":"1726_CR29","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S0002-9343(55)80017-4","volume":"19","author":"RS Schwab","year":"1955","unstructured":"Schwab RS. WIN 8077 in the treatment of sixty myasthenia gravis patients: a twelve-month report. Am J Med. 1955;19(5):734\u20136.","journal-title":"Am J Med"},{"issue":"5","key":"1726_CR30","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0026-895X(25)09170-9","volume":"41","author":"AS Hodge","year":"1992","unstructured":"Hodge AS, Humphrey DR, Rosenberry TL. Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities. Mol Pharmacol. 1992;41(5):937\u201342.","journal-title":"Mol Pharmacol"},{"key":"1726_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/DDDT.S25716","volume":"7","author":"C Angelini","year":"2013","unstructured":"Angelini C, Martignago S, Bisciglia M. New treatments for myasthenia: a focus on antisense oligonucleotides. Drug Des Devel Ther. 2013;7:13\u20137.","journal-title":"Drug Des Devel Ther."},{"key":"1726_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1749-6632.2012.06825.x","volume":"1275","author":"J Sussman","year":"2012","unstructured":"Sussman J, Argov Z, Wirguin Y, Apolski S, Milic-Rasic V, Soreq H. Further developments with antisense treatment for myasthenia gravis. Ann N Y Acad Sci. 2012;1275:13\u20136.","journal-title":"Ann N Y Acad Sci"},{"issue":"406","key":"1726_CR33","doi-asserted-by":"publisher","first-page":"116428","DOI":"10.1016\/j.jns.2019.116428","volume":"15","author":"TM Nguyen-Cao","year":"2019","unstructured":"Nguyen-Cao TM, Gelinas D, Griffin R, Mondou E. Myasthenia gravis: historical achievements and the \u201cgolden age\u201d of clinical trials. J Neurol Sci. 2019;15(406):116428.","journal-title":"J Neurol Sci"},{"issue":"1","key":"1726_CR34","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1212\/01.wnl.0000167132.35865.31","volume":"65","author":"M Bestue-Cardiel","year":"2005","unstructured":"Bestue-Cardiel M, S\u00e1enz de Cabez\u00f3n-Alvarez A, Capablo-Liesa JL, L\u00f3pez-Pis\u00f3n J, Pe\u00f1a-Segura JL, Martin-Martinez J, et al. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology. 2005;65(1):144\u20136.","journal-title":"Neurology"},{"issue":"19","key":"1726_CR35","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1212\/WNL.0b013e3181dd43bf","volume":"74","author":"D Lashley","year":"2010","unstructured":"Lashley D, Palace J, Jayawant S, Robb S, Beeson D. Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7(LOE Classification). Neurology. 2010;74(19):1517\u201323.","journal-title":"Neurology"},{"issue":"2","key":"1726_CR36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/mus.22153","volume":"44","author":"M Sadeh","year":"2011","unstructured":"Sadeh M, Shen X-M, Engel AG. Beneficial effect of albuterol in congential myasthenic syndrome with epsilon subuint mutations. Muscle Nerve. 2011;44(2):289\u201391.","journal-title":"Muscle Nerve"},{"issue":"5","key":"1726_CR37","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mus.22176","volume":"44","author":"T Liewluck","year":"2011","unstructured":"Liewluck T, Selcen D, Engel AG. Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and DOK-7 Myasthenia. Muscle Nerve. 2011;44(5):789\u201394.","journal-title":"Muscle Nerve"},{"issue":"12","key":"1726_CR38","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1093\/brain\/awz322","volume":"142","author":"AE Vanhaesebrouck","year":"2019","unstructured":"Vanhaesebrouck AE, Webster R, Maxwell S, Rodriguez Cruz PM, Cossins J, Wickens J, et al. \u03b22-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure. Brain. 2019;142(12):3713\u201327.","journal-title":"Brain"},{"key":"#cr-split#-1726_CR39.1","unstructured":"Thomsen JLS (2020) Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis [Internet]. clinicaltrials.gov"},{"key":"#cr-split#-1726_CR39.2","unstructured":"2020 Apr [cited 2021 Dec 22]. Report No.: NCT03914638. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03914638"},{"issue":"2","key":"1726_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141\u20139.","journal-title":"Muscle Nerve"},{"issue":"3","key":"1726_CR41","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"issue":"6","key":"1726_CR42","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/ncpneuro0810","volume":"4","author":"S Sathasivam","year":"2008","unstructured":"Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Rev Neurol. 2008;4(6):317\u201327.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"1726_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1056\/NEJM197201062860104","volume":"286","author":"JR Warmolts","year":"1972","unstructured":"Warmolts JR, Engel WK. Benefit from alternate-day prednisone in myasthenia gravis. N Engl J Med. 1972;286(1):17\u201320.","journal-title":"N Engl J Med"},{"issue":"7754","key":"1726_CR44","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0140-6736(72)90520-X","volume":"1","author":"RB Jenkins","year":"1972","unstructured":"Jenkins RB. Treatment of myasthenia gravis with prednisone. Lancet. 1972;1(7754):765\u20137.","journal-title":"Lancet"},{"key":"1726_CR45","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1749-6632.1976.tb47718.x","volume":"274","author":"FM Howard","year":"1976","unstructured":"Howard FM, Duane DD, Lambert EH, Daube JR. Alternate-day prednisone: preliminary report of a double-blind controlled study. Ann N Y Acad Sci. 1976;274:596\u2013607.","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"1726_CR46","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.410150316","volume":"15","author":"RM Pascuzzi","year":"1984","unstructured":"Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984;15(3):291\u20138.","journal-title":"Ann Neurol"},{"issue":"2","key":"1726_CR47","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1212\/WNL.34.2.170","volume":"34","author":"A Sghirlanzoni","year":"1984","unstructured":"Sghirlanzoni A, Peluchetti D, Mantegazza R, Fiacchino F, Cornelio F. Myasthenia gravis: prolonged treatment with steroids. Neurology. 1984;34(2):170\u20134.","journal-title":"Neurology"},{"issue":"2","key":"1726_CR48","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","volume":"36","author":"C Farmakidis","year":"2018","unstructured":"Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of myasthenia gravis. Neurol Clin. 2018;36(2):311\u201337.","journal-title":"Neurol Clin"},{"issue":"6","key":"1726_CR49","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","volume":"97","author":"C Lindberg","year":"1998","unstructured":"Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand. 1998;97(6):370\u20133.","journal-title":"Acta Neurol Scand"},{"issue":"12","key":"1726_CR50","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1001\/archneur.1985.04060110031011","volume":"42","author":"E Arsura","year":"1985","unstructured":"Arsura E, Brunner NG, Namba T, Grob D. High-dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol. 1985;42(12):1149\u201353.","journal-title":"Arch Neurol"},{"issue":"412","key":"1726_CR51","doi-asserted-by":"publisher","first-page":"116740","DOI":"10.1016\/j.jns.2020.116740","volume":"15","author":"T Sugimoto","year":"2020","unstructured":"Sugimoto T, Ochi K, Ishikawa R, Tazuma T, Hayashi M, Mine N, et al. Initial deterioration and intravenous methylprednisolone therapy in patients with myasthenia gravis. J Neurol Sci. 2020;15(412):116740.","journal-title":"J Neurol Sci"},{"issue":"10","key":"1726_CR52","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","volume":"13","author":"JS Bae","year":"2006","unstructured":"Bae JS, Go SM, Kim BJ. Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J Clin Neurosci. 2006;13(10):1006\u201310.","journal-title":"J Clin Neurosci"},{"issue":"12","key":"1726_CR53","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1007\/s00415-020-10264-0","volume":"268","author":"I Lotan","year":"2021","unstructured":"Lotan I, Hellmann MA, Wilf-Yarkoni A, Steiner I. Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review. J Neurol. 2021;268(12):4573\u201386.","journal-title":"J Neurol"},{"issue":"2","key":"1726_CR54","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1056\/NEJM197401102900204","volume":"290","author":"ME Seybold","year":"1974","unstructured":"Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med. 1974;290(2):81\u20134.","journal-title":"N Engl J Med"},{"issue":"5","key":"1726_CR55","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/mus.24438","volume":"51","author":"T Imai","year":"2015","unstructured":"Imai T, Suzuki S, Tsuda E, Nagane Y, Murai H, Masuda M, et al. Oral corticosteroid therapy and present disease status in myasthenia gravis. Muscle Nerve. 2015;51(5):692\u20136.","journal-title":"Muscle Nerve"},{"issue":"4","key":"1726_CR56","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/jamaneurol.2020.5407","volume":"78","author":"T Sharshar","year":"2021","unstructured":"Sharshar T, Porcher R, Demeret S, Tranchant C, Gueguen A, Eymard B, et al. Comparison of corticosteroid tapering regimens in myasthenia gravis: a randomized clinical trial. JAMA Neurol. 2021;78(4):426\u201333.","journal-title":"JAMA Neurol"},{"issue":"8","key":"1726_CR57","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1172\/JCI200318384","volume":"111","author":"JS Maltzman","year":"2003","unstructured":"Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Invest. 2003;111(8):1122\u20134.","journal-title":"J Clin Invest"},{"issue":"8","key":"1726_CR58","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1172\/JCI16432","volume":"111","author":"I Tiede","year":"2003","unstructured":"Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111(8):1133\u201345.","journal-title":"J Clin Invest"},{"key":"1726_CR59","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1749-6632.1981.tb33767.x","volume":"377","author":"HG Mertens","year":"1981","unstructured":"Mertens HG, Hertel G, Reuther P, Ricker K. Effect of immunosuppressive drugs (azathioprine). Ann N Y Acad Sci. 1981;377:691\u20139.","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"1726_CR60","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/BF00314245","volume":"235","author":"R Mantegazza","year":"1988","unstructured":"Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol. 1988;235(8):449\u201353.","journal-title":"J Neurol"},{"issue":"6","key":"1726_CR61","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/ana.410150615","volume":"15","author":"AS Witte","year":"1984","unstructured":"Witte AS, Cornblath DR, Parry GJ, Lisak RP, Schatz NJ. Azathioprine in the treatment of myasthenia gravis. Ann Neurol. 1984;15(6):602\u20135.","journal-title":"Ann Neurol"},{"key":"1726_CR62","doi-asserted-by":"crossref","unstructured":"A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group. J Neurol Neurosurg Psychiatry. 1993;56(11):1157\u201363.","DOI":"10.1136\/jnnp.56.11.1157"},{"issue":"1","key":"1726_CR63","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0022-510X(97)05370-7","volume":"150","author":"M Bromberg","year":"1997","unstructured":"Bromberg M, Wald J, Forshew D, Feldman E, Albers J. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci. 1997;150(1):59\u201362.","journal-title":"J Neurol Sci"},{"issue":"6","key":"1726_CR64","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50(6):1778\u201383.","journal-title":"Neurology"},{"issue":"772","key":"1726_CR65","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/pgmj.66.772.102","volume":"66","author":"V Fonseca","year":"1990","unstructured":"Fonseca V, Havard CW. Long term treatment of myasthenia gravis with azathioprine. Postgrad Med J. 1990;66(772):102\u20135.","journal-title":"Postgrad Med J"},{"issue":"2","key":"1726_CR66","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1212\/WNL.38.2.258","volume":"38","author":"R Hohlfeld","year":"1988","unstructured":"Hohlfeld R, Michels M, Heininger K, Besinger U, Toyka KV. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology. 1988;38(2):258\u201361.","journal-title":"Neurology"},{"issue":"3","key":"1726_CR67","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/00008571-200403000-00006","volume":"14","author":"AM Marinaki","year":"2004","unstructured":"Marinaki AM, Ansari A, Duley JA, Arenas M, Sumi S, Lewis CM, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics. 2004;14(3):181\u20137.","journal-title":"Pharmacogenetics"},{"issue":"6","key":"1726_CR68","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/tpj.2014.47","volume":"14","author":"HF Burnett","year":"2014","unstructured":"Burnett HF, Tanoshima R, Chandranipapongse W, Madadi P, Ito S, Ungar WJ. Testing for thiopurine methyltransferase status for safe and effective thiopurine administration: a systematic review of clinical guidance documents. Pharmacogenomics J. 2014;14(6):493\u2013502.","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"1726_CR69","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/ene.12108","volume":"20","author":"EG Pedersen","year":"2013","unstructured":"Pedersen EG, Potteg\u00e5rd A, Hallas J, Friis S, Hansen K, Jensen PEH, et al. Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark. Eur J Neurol. 2013;20(6):942\u20138.","journal-title":"Eur J Neurol"},{"issue":"5","key":"1726_CR70","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"CG Skorpen","year":"2016","unstructured":"Skorpen CG, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795\u2013810.","journal-title":"Ann Rheum Dis"},{"key":"1726_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/cjn.2021.2","volume":"12","author":"M Alharbi","year":"2021","unstructured":"Alharbi M, Menon D, Barnett C, Katzberg H, Sermer M, Bril V. Myasthenia Gravis and Pregnancy: Toronto Specialty Center Experience. Can J Neurol Sci. 2021;12:1\u20135.","journal-title":"Can J Neurol Sci"},{"issue":"2\u20133","key":"1726_CR72","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2\u20133):85\u2013118.","journal-title":"Immunopharmacology"},{"issue":"1","key":"1726_CR73","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1212\/WNL.56.1.94","volume":"56","author":"V Chaudhry","year":"2001","unstructured":"Chaudhry V, Cornblath DR, Griffin JW, O\u2019Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology. 2001;56(1):94\u20136.","journal-title":"Neurology"},{"issue":"6","key":"1726_CR74","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","volume":"71","author":"Muscle Study Group","year":"2008","unstructured":"Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71(6):394\u20139.","journal-title":"Neurology"},{"issue":"6","key":"1726_CR75","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"DB Sanders","year":"2008","unstructured":"Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MHV, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71(6):400\u20136.","journal-title":"Neurology"},{"issue":"4","key":"1726_CR76","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"issue":"5","key":"1726_CR77","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/mus.21640","volume":"41","author":"MK Hehir","year":"2010","unstructured":"Hehir MK, Burns TM, Alpers J, Conaway MR, Sawa M, Sanders DB. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve. 2010;41(5):593\u20138.","journal-title":"Muscle Nerve"},{"issue":"3","key":"1726_CR78","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","volume":"15","author":"J Sussman","year":"2015","unstructured":"Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D. Myasthenia gravis: Association of British Neurologists\u2019 management guidelines. Pract Neurol. 2015;15(3):199\u2013206.","journal-title":"Pract Neurol"},{"issue":"3","key":"1726_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20517\/2347-8659.2015.60","volume":"20","author":"Z-Y Li","year":"2016","unstructured":"Li Z-Y. China guidelines for the diagnosis and treatment of myasthenia gravis. Neuroimmunol Neuroinflamm. 2016;20(3):1\u20139.","journal-title":"Neuroimmunol Neuroinflamm."},{"issue":"8","key":"1726_CR80","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/2047-783X-14-8-364","volume":"14","author":"F Hanisch","year":"2009","unstructured":"Hanisch F, Wendt M, Zierz S. Mycophenolate mofetil as second line immunosuppressant in myasthenia gravis\u2014a long-term prospective open-label study. Eur J Med Res. 2009;14(8):364\u20136.","journal-title":"Eur J Med Res"},{"issue":"2","key":"1726_CR81","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","volume":"47","author":"S Matsuda","year":"2000","unstructured":"Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47(2):119\u201325.","journal-title":"Immunopharmacology"},{"issue":"12","key":"1726_CR82","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM198703193161205","volume":"316","author":"RSA Tindall","year":"1987","unstructured":"Tindall RSA, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987;316(12):719\u201324.","journal-title":"N Engl J Med"},{"issue":"4","key":"1726_CR83","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1600-0404.2005.00378.x","volume":"111","author":"D Lavrnic","year":"2005","unstructured":"Lavrnic D, Vujic A, Rakocevic-Stojanovic V, Stevic Z, Basta I, Pavlovic S, et al. Cyclosporine in the treatment of myasthenia gravis. Acta Neurol Scand. 2005;111(4):247\u201352.","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"1726_CR84","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/01.cnd.0000249871.11436.f8","volume":"8","author":"N Souayah","year":"2006","unstructured":"Souayah N, Khella SL. Low dose of cyclosporine in myasthenia gravis. J Clin Neuromuscul Dis. 2006;8(2):75\u20139.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"3","key":"1726_CR85","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000319172","volume":"64","author":"Y Nagane","year":"2010","unstructured":"Nagane Y, Suzuki S, Suzuki N, Utsugisawa K. Two-year treatment with cyclosporine microemulsion for responder myasthenia gravis patients. Eur Neurol. 2010;64(3):186\u201390.","journal-title":"Eur Neurol"},{"issue":"2","key":"1726_CR86","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1756285615571873","volume":"8","author":"JL Cruz","year":"2015","unstructured":"Cruz JL, Wolff ML, Vanderman AJ, Brown JN. The emerging role of tacrolimus in myasthenia gravis. Ther Adv Neurol Disord. 2015;8(2):92\u2013103.","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"1726_CR87","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/jnnp-2011-300148","volume":"82","author":"H Yoshikawa","year":"2011","unstructured":"Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011;82(9):970\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"1726_CR88","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1756285617721092","volume":"10","author":"L Zhou","year":"2017","unstructured":"Zhou L, Liu W, Li W, Li H, Zhang X, Shang H, et al. Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China. Ther Adv Neurol Disord. 2017;10(9):315\u201325.","journal-title":"Ther Adv Neurol Disord"},{"key":"1726_CR89","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3389\/fneur.2020.594152","volume":"11","author":"Z Fan","year":"2020","unstructured":"Fan Z, Li Z, Shen F, Zhang X, Lei L, Su S, et al. Favorable effects of tacrolimus monotherapy on myasthenia gravis patients. Front Neurol. 2020;11:1306.","journal-title":"Front Neurol"},{"issue":"5","key":"1726_CR90","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1053\/j.ajkd.2008.11.033","volume":"53","author":"S Choudhry","year":"2009","unstructured":"Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis. 2009;53(5):760\u20139.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1726_CR91","first-page":"168","volume":"65","author":"H Tian","year":"2007","unstructured":"Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(3):168\u201373.","journal-title":"Bull NYU Hosp Jt Dis"},{"issue":"11","key":"1726_CR92","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1471-2377-11-97","volume":"5","author":"JM Heckmann","year":"2011","unstructured":"Heckmann JM, Rawoot A, Bateman K, Renison R, Badri M. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol. 2011;5(11):97.","journal-title":"BMC Neurol"},{"issue":"1","key":"1726_CR93","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","volume":"87","author":"M Pasnoor","year":"2016","unstructured":"Pasnoor M, He J, Herbelin L, Burns TM, Nations S, Bril V, et al. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology. 2016;87(1):57\u201364.","journal-title":"Neurology"},{"issue":"4","key":"1726_CR94","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jbspin.2006.01.007","volume":"73","author":"S Pavy","year":"2006","unstructured":"Pavy S, Constantin A, Pham T, Gossec L, Maillefert J-F, Cantagrel A, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 2006;73(4):388\u201395.","journal-title":"Joint Bone Spine"},{"issue":"4","key":"1726_CR95","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00280-016-3152-1","volume":"78","author":"M Ahlmann","year":"2016","unstructured":"Ahlmann M, Hempel G. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol. 2016;78(4):661\u201371.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1726_CR96","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1212\/WNL.31.1.32","volume":"31","author":"MC Perez","year":"1981","unstructured":"Perez MC, Buot WL, Mercado-Danguilan C, Bagabaldo ZG, Renales LD. Stable remissions in myasthenia gravis. Neurology. 1981;31(1):32\u20137.","journal-title":"Neurology"},{"issue":"1","key":"1726_CR97","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mus.10133","volume":"26","author":"LG De Feo","year":"2002","unstructured":"De Feo LG, Schottlender J, Martelli NA, Molfino NA. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve. 2002;26(1):31\u20136.","journal-title":"Muscle Nerve"},{"issue":"11","key":"1726_CR98","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.jocn.2014.03.019","volume":"21","author":"M Nagappa","year":"2014","unstructured":"Nagappa M, Netravathi M, Taly AB, Sinha S, Bindu PS, Mahadevan A. Long-term efficacy and limitations of cyclophosphamide in myasthenia gravis. J Clin Neurosci. 2014;21(11):1909\u201314.","journal-title":"J Clin Neurosci"},{"issue":"3","key":"1726_CR99","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00415-019-09622-4","volume":"267","author":"E Gomez-Figueroa","year":"2020","unstructured":"Gomez-Figueroa E, Garcia-Trejo S, Bazan-Rodriguez L, Cervantes-Uribe R, Chac-Lezama G, L\u00f3pez-Hern\u00e1ndez JC, et al. Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis. J Neurol. 2020;267(3):674\u20138.","journal-title":"J Neurol"},{"issue":"2","key":"1726_CR100","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/mus.24536","volume":"52","author":"KA Buzzard","year":"2015","unstructured":"Buzzard KA, Meyer NJ, Hardy TA, Riminton DS, Reddel SW. Induction intravenous cyclophosphamide followed by maintenance oral immunosuppression in refractory myasthenia gravis. Muscle Nerve. 2015;52(2):204\u201310.","journal-title":"Muscle Nerve"},{"issue":"10","key":"1726_CR101","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.autrev.2018.04.007","volume":"17","author":"C Ponticelli","year":"2018","unstructured":"Ponticelli C, Escoli R, Moroni G. Does cyclophosphamide still play a role in glomerular diseases? Autoimmun Rev. 2018;17(10):1022\u20137.","journal-title":"Autoimmun Rev"},{"issue":"Suppl 3","key":"1726_CR102","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00415-008-3002-0","volume":"255","author":"H-P Hartung","year":"2008","unstructured":"Hartung H-P. Advances in the understanding of the mechanism of action of IVIg. J Neurol. 2008;255(Suppl 3):3\u20136.","journal-title":"J Neurol"},{"issue":"8373","key":"1726_CR103","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S0140-6736(84)90469-0","volume":"1","author":"P Gajdos","year":"1984","unstructured":"Gajdos P, Outin H, Elkharrat D, Brunel D, de Rohan-Chabot P, Raphael JC, et al. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1984;1(8373):406\u20137.","journal-title":"Lancet"},{"issue":"11","key":"1726_CR104","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","volume":"68","author":"L Zinman","year":"2007","unstructured":"Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68(11):837\u201341.","journal-title":"Neurology"},{"issue":"23","key":"1726_CR105","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017\u201323.","journal-title":"Neurology"},{"issue":"12","key":"1726_CR106","first-page":"CD002277","volume":"2012","author":"P Gajdos","year":"2012","unstructured":"Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2012;2012(12):CD002277.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5\u20136","key":"1726_CR107","first-page":"223","volume":"81","author":"G Karelis","year":"2019","unstructured":"Karelis G, Balasa R, De Bleecker JL, Stuchevskaya T, Villa A, Van Damme P, et al. A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate\/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations. ENE. 2019;81(5\u20136):223\u201330.","journal-title":"ENE"},{"issue":"5","key":"1726_CR108","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamaneurol.2014.17","volume":"71","author":"WKM Liew","year":"2014","unstructured":"Liew WKM, Powell CA, Sloan SR, Shamberger RC, Weldon CB, Darras BT, et al. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurol. 2014;71(5):575\u201380.","journal-title":"JAMA Neurol"},{"issue":"6","key":"1726_CR109","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10072-013-1621-4","volume":"35","author":"MH Sorgun","year":"2014","unstructured":"Sorgun MH, Sener HO, Yucesan C, Yucemen N. Intravenous immunoglobulin for prophylaxis of acute exacerbation in Myasthenia Gravis. Neurol Sci. 2014;35(6):891\u20136.","journal-title":"Neurol Sci"},{"issue":"1\u20132","key":"1726_CR110","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jns.2013.10.043","volume":"338","author":"MA Hellmann","year":"2014","unstructured":"Hellmann MA, Mosberg-Galili R, Lotan I, Steiner I. Maintenance IVIg therapy in myasthenia gravis does not affect disease activity. J Neurol Sci. 2014;338(1\u20132):39\u201342.","journal-title":"J Neurol Sci"},{"issue":"9","key":"1726_CR111","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","volume":"8","author":"Y Guo","year":"2018","unstructured":"Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;8(9):1299.","journal-title":"Front Immunol"},{"issue":"4","key":"1726_CR112","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","volume":"6","author":"U Katz","year":"2007","unstructured":"Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007;6(4):257\u20139.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"1726_CR113","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2174\/157015909790031166","volume":"7","author":"S Jacob","year":"2009","unstructured":"Jacob S, Rajabally YA. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol. 2009;7(4):337\u201342.","journal-title":"Curr Neuropharmacol"},{"issue":"5","key":"1726_CR114","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/NAN.0000000000000240","volume":"40","author":"VM Rasutis","year":"2017","unstructured":"Rasutis VM, Katzberg HD, Bril V. High-dose subcutaneous immunoglobulin in patients with multifocal motor neuropathy: a nursing perspective. J Infus Nurs. 2017;40(5):305\u201312.","journal-title":"J Infus Nurs"},{"issue":"1","key":"1726_CR115","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/1756285614563056","volume":"8","author":"RDM Hadden","year":"2015","unstructured":"Hadden RDM, Marreno F. Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction. Ther Adv Neurol Disord. 2015;8(1):14\u20139.","journal-title":"Ther Adv Neurol Disord"},{"key":"1726_CR116","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jocn.2019.08.113","volume":"72","author":"KJB Adiao","year":"2020","unstructured":"Adiao KJB, Espiritu AI, Roque VLA, Reyes JPBT. Efficacy and tolerability of subcutaneously administered immunoglobulin in myasthenia gravis: a systematic review. J Clin Neurosci. 2020;72:316\u201321.","journal-title":"J Clin Neurosci"},{"issue":"2","key":"1726_CR117","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/ene.14547","volume":"28","author":"M Alcantara","year":"2021","unstructured":"Alcantara M, Sarpong E, Barnett C, Katzberg H, Bril V. Chronic immunoglobulin maintenance therapy in myasthenia gravis. Eur J Neurol. 2021;28(2):639\u201346.","journal-title":"Eur J Neurol"},{"issue":"11","key":"1726_CR118","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1212\/WNL.0000000000004365","volume":"89","author":"G Beecher","year":"2017","unstructured":"Beecher G, Anderson D, Siddiqi ZA. Subcutaneous immunoglobulin in myasthenia gravis exacerbation: a prospective, open-label trial. Neurology. 2017;89(11):1135\u201341.","journal-title":"Neurology"},{"key":"1726_CR119","first-page":"1","volume":"26","author":"D Menon","year":"2021","unstructured":"Menon D, Sarpong E, Bril V. Practical aspects of transitioning from intravenous to subcutaneous immunoglobulin therapy in neuromuscular disorders. Can J Neurol Sci. 2021;26:1\u20137.","journal-title":"Can J Neurol Sci"},{"key":"1726_CR120","unstructured":"Katzberg H. Efficacy and Safety of Subcutaneous Immunoglobulin in Patients With Myasthenia Gravis [Internet]. clinicaltrials.gov; 2021 Jan [cited 2021 Dec 14]. Report No.: NCT04728425. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04728425"},{"issue":"3","key":"1726_CR121","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/bjh.12629","volume":"164","author":"HM Reeves","year":"2014","unstructured":"Reeves HM, Winters JL. The mechanisms of action of plasma exchange. Br J Haematol. 2014;164(3):342\u201351.","journal-title":"Br J Haematol"},{"key":"1726_CR122","doi-asserted-by":"crossref","unstructured":"Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice\u2013Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. Journal of Clinical Apheresis. 2016;31(3):149\u2013338.","DOI":"10.1002\/jca.21470"},{"issue":"7","key":"1726_CR123","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1080\/08916934.2016.1214823","volume":"49","author":"JT Guptill","year":"2016","unstructured":"Guptill JT, Juel VC, Massey JM, Anderson AC, Chopra M, Yi JS, et al. Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis. Autoimmunity. 2016;49(7):472\u20139.","journal-title":"Autoimmunity"},{"issue":"8000","key":"1726_CR124","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0140-6736(76)91917-6","volume":"308","author":"AJ Pinching","year":"1976","unstructured":"Pinching AJ, Peters DK, Davis JN. Remission of myasthenia gravis following plasma-exchange. Lancet. 1976;308(8000):1373\u20136.","journal-title":"Lancet"},{"key":"1726_CR125","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3389\/fneur.2021.662856","volume":"12","author":"TS Ipe","year":"2021","unstructured":"Ipe TS, Davis AR, Raval JS. Therapeutic plasma exchange in myasthenia gravis: a systematic literature review and meta-analysis of comparative evidence. Front Neurol. 2021;12:1355.","journal-title":"Front Neurol"},{"issue":"3","key":"1726_CR126","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/CND.0b013e3181660807","volume":"9","author":"P Jensen","year":"2008","unstructured":"Jensen P, Bril V. A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis. J Clin Neuromuscul Dis. 2008;9(3):352\u20135.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"1","key":"1726_CR127","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s13760-016-0689-z","volume":"117","author":"A Alipour-Faz","year":"2017","unstructured":"Alipour-Faz A, Shojaei M, Peyvandi H, Ramzi D, Oroei M, Ghadiri F, et al. A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients. Acta Neurol Belg. 2017;117(1):245\u20139.","journal-title":"Acta Neurol Belg"},{"issue":"12","key":"1726_CR128","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","volume":"25","author":"J R\u00f8nager","year":"2001","unstructured":"R\u00f8nager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs. 2001;25(12):967\u201373.","journal-title":"Artif Organs"},{"issue":"1","key":"1726_CR129","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","volume":"44","author":"JT Guptill","year":"2011","unstructured":"Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36\u201340.","journal-title":"Muscle Nerve"},{"issue":"1","key":"1726_CR130","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","volume":"1412","author":"JF Howard","year":"2018","unstructured":"Howard JF. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018;1412(1):113\u201328.","journal-title":"Ann N Y Acad Sci"},{"key":"1726_CR131","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3389\/fimmu.2020.00917","volume":"11","author":"K Albazli","year":"2020","unstructured":"Albazli K, Kaminski HJ, Howard JF. Complement inhibitor therapy for myasthenia gravis. Front Immunol. 2020;11:917.","journal-title":"Front Immunol"},{"issue":"11","key":"1726_CR132","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25(11):1256\u201364.","journal-title":"Nat Biotechnol"},{"issue":"3","key":"1726_CR133","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S. Eculizumab: a review in generalized myasthenia gravis. Drugs. 2018;78(3):367\u201376.","journal-title":"Drugs"},{"issue":"1","key":"1726_CR134","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/mus.23839","volume":"48","author":"JF Howard Jr","year":"2013","unstructured":"Howard JF Jr, Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48(1):76\u201384.","journal-title":"Muscle Nerve"},{"issue":"12","key":"1726_CR135","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. The Lancet Neurology. 2017;16(12):976\u201386.","journal-title":"The Lancet Neurology."},{"issue":"5","key":"1726_CR136","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/13543784.2021.1897567","volume":"30","author":"JF Howard","year":"2021","unstructured":"Howard JF, Vissing J, Gilhus NE, Leite MI, Utsugisawa K, Duda PW, et al. Zilucoplan: an investigational complement C5 inhibitor for the treatment of acetylcholine receptor autoantibody-positive generalized myasthenia gravis. Expert Opin Investig Drugs. 2021;30(5):483\u201393.","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"1726_CR137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaneurol.2019.5125","volume":"77","author":"JF Howard","year":"2020","unstructured":"Howard JF, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, et al. Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis. JAMA Neurol. 2020;77(5):1\u201311.","journal-title":"JAMA Neurol"},{"key":"1726_CR138","unstructured":"Carvalho J. Potential MG Treatment, Zilucoplan, Named Orphan Drug by FDA [Internet]. [cited 2021 Nov 19]. https:\/\/myastheniagravisnews.com\/news-posts\/2019\/09\/05\/fda-grants-orphan-drug-status-to-ra-pharmas-zilucoplan-for-mg\/"},{"key":"1726_CR139","unstructured":"Ra Pharmaceuticals. A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis [Internet]. clinicaltrials.gov; 2021 Nov [cited 2021 Nov 18]. Report No.: NCT04115293. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04115293"},{"key":"1726_CR140","unstructured":"761108Orig1s000ChemR.pdf [Internet]. [cited 2021 Nov 21]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/761108Orig1s000ChemR.pdf"},{"issue":"4","key":"1726_CR141","doi-asserted-by":"publisher","first-page":"e0195909","DOI":"10.1371\/journal.pone.0195909","volume":"13","author":"D Sheridan","year":"2018","unstructured":"Sheridan D, Yu Z-X, Zhang Y, Patel R, Sun F, Lasaro MA, et al. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. PLoS ONE. 2018;13(4):e0195909.","journal-title":"PLoS ONE"},{"issue":"10","key":"1726_CR142","first-page":"204062071987472","volume":"10","author":"RM Stern","year":"2019","unstructured":"Stern RM, Connell NT. Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol. 2019;10(10):2040620719874728.","journal-title":"Ther Adv Hematol."},{"key":"1726_CR143","unstructured":"PhD FR. Ultomiris Helps Ease Severity of gMG Symptoms in Phase 3 Trial [Internet]. [cited 2021 Nov 21]. https:\/\/myastheniagravisnews.com\/news-posts\/2021\/07\/20\/ultomiris-helps-ease-gmg-symptoms-phase-3-trial-ongoing-extension-study\/"},{"key":"1726_CR144","unstructured":"Alexion Pharmaceuticals. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Na\u00efve Adult Patients With Generalized Myasthenia Gravis [Internet]. clinicaltrials.gov; 2021 Sep [cited 2021 Nov 18]. Report No.: NCT03920293. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03920293"},{"key":"1726_CR145","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","volume":"10","author":"M Pyzik","year":"2019","unstructured":"Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS. The Neonatal Fc Receptor (FcRn): A Misnomer? Front Immunol. 2019;10:1540.","journal-title":"Front Immunol"},{"issue":"9","key":"1726_CR146","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715\u201325.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"1726_CR147","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","volume":"10","author":"KL Gable","year":"2020","unstructured":"Gable KL, Guptill JT. Antagonism of the neonatal Fc receptor as an emerging treatment for myasthenia gravis. Front Immunol. 2020;10(10):3052.","journal-title":"Front Immunol"},{"issue":"10","key":"1726_CR148","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372\u201386.","journal-title":"J Clin Invest"},{"key":"1726_CR149","doi-asserted-by":"crossref","unstructured":"Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 128(10):4372\u201386.","DOI":"10.1172\/JCI97911"},{"issue":"23","key":"1726_CR150","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","volume":"92","author":"JF Howard","year":"2019","unstructured":"Howard JF, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661\u201373.","journal-title":"Neurology"},{"issue":"7","key":"1726_CR151","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard","year":"2021","unstructured":"Howard JF, Bril V, Vu T, Karam C, Peric S, Margania T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"key":"1726_CR152","unstructured":"Commissioner O of the. FDA Approves New Treatment for Myasthenia Gravis [Internet]. FDA. FDA; 2021 [cited 2022 Jan 19]. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-myasthenia-gravis"},{"issue":"3","key":"1726_CR153","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"Y-A Heo","year":"2022","unstructured":"Heo Y-A. Efgartigimod: first approval. Drugs. 2022;82(3):341\u20138.","journal-title":"Drugs"},{"key":"1726_CR154","unstructured":"argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation [Internet]. Argenx. [cited 2022 Apr 5]. https:\/\/www.argenx.com\/news\/argenx-announces-data-phase-1-study-efgartigimod-argx-113-subcutaneous-formulation"},{"key":"1726_CR155","unstructured":"argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis [Internet]. 2022 [cited 2022 Apr 5]. https:\/\/www.businesswire.com\/news\/home\/20220321005941\/en\/argenx-Announces-Positive-Topline-Phase-3-Data-From-ADAPT-SC-Study-Evaluating-Subcutaneous-Efgartigimod-for-Generalized-Myasthenia-Gravis"},{"issue":"414","key":"1726_CR156","doi-asserted-by":"publisher","first-page":"eaan1208","DOI":"10.1126\/scitranslmed.aan1208","volume":"9","author":"P Kiessling","year":"2017","unstructured":"Kiessling P, Lledo-Garcia R, Watanabe S, Langdon G, Tran D, Bari M, et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Sci Transl Med. 2017;9(414):eaan1208.","journal-title":"Sci Transl Med."},{"issue":"6","key":"1726_CR157","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","volume":"96","author":"V Bril","year":"2021","unstructured":"Bril V, Benatar M, Andersen H, Vissing J, Brock M, Greve B, et al. Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis: a phase 2 randomized control trial. Neurology. 2021;96(6):e853\u201365.","journal-title":"Neurology"},{"key":"1726_CR158","unstructured":"UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis | UCB [Internet]. [cited 2022 Jan 19]. https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-announces-positive-Phase-3-results-for-rozanolixizumab-in-generalized-myasthenia-gravis"},{"issue":"4","key":"1726_CR159","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/cpt.1276","volume":"105","author":"LE Ling","year":"2019","unstructured":"Ling LE, Hillson JL, Tiessen RG, Bosje T, van Iersel MP, Nix DJ, et al. M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study. Clin Pharmacol Ther. 2019;105(4):1031\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1726_CR160","doi-asserted-by":"crossref","unstructured":"Guptill J, Antozzi C, Bril V, Gamez J, Meuth SG, Blanco JLM, et al. Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis (2157). Neurology [Internet]. 2021 Apr 13 [cited 2021 Dec 1];96(15 Supplement). https:\/\/n.neurology.org\/content\/96\/15_Supplement\/2157","DOI":"10.1212\/WNL.96.15_supplement.2157"},{"key":"1726_CR161","unstructured":"Janssen Research & Development, LLC. Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis [Internet]. clinicaltrials.gov; 2021 Nov [cited 2021 Nov 29]. Report No.: NCT04951622. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04951622"},{"issue":"5","key":"1726_CR162","doi-asserted-by":"publisher","first-page":"498.e1","DOI":"10.1016\/j.ajog.2019.02.058","volume":"220","author":"S Roy","year":"2019","unstructured":"Roy S, Nanovskaya T, Patrikeeva S, Cochran E, Parge V, Guess J, et al. M281, an anti-FcRn antibody, inhibits IgG transfer in a human ex vivo placental perfusion model. Am J Obstet Gynecol. 2019;220(5):498.e1-498.e9.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"1726_CR163","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/bjh.17041","volume":"192","author":"JS Castleman","year":"2021","unstructured":"Castleman JS, Moise KJ Jr, Kilby MD. Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation. Br J Haematol. 2021;192(3):425\u201332.","journal-title":"Br J Haematol"},{"key":"1726_CR164","doi-asserted-by":"crossref","unstructured":"Collins J, Jones L, Snyder M, Sicard \u00c9, Griffin P, Webster L, et al. RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration (P5.2-079). undefined [Internet]. 2019 [cited 2021 Dec 1]; https:\/\/www.semanticscholar.org\/paper\/RVT-1401%2C-A-Novel-Anti-FcRn-Monoclonal-Antibody%2C-Is-Collins-Jones\/3391016595f96d3dc5e86bdddc670e36578eb1a9","DOI":"10.1212\/WNL.92.15_supplement.P5.2-079"},{"issue":"5","key":"1726_CR165","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1111\/cts.13019","volume":"14","author":"DYH Yap","year":"2021","unstructured":"Yap DYH, Hai J, Lee PCH, Zhou X, Lee M, Zhang Y, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers. Clin Transl Sci. 2021;14(5):1769\u201379.","journal-title":"Clin Transl Sci"},{"key":"1726_CR166","unstructured":"PhD MF. Batoclimab Effective and Safe With Generalized MG, Phase 2 Trial Finds [Internet]. [cited 2021 Dec 1]. https:\/\/myastheniagravisnews.com\/news-posts\/2021\/07\/13\/batoclimab-effective-safe-generalized-mg-phase-2-top-line-data\/"},{"key":"1726_CR167","unstructured":"Harbour BioMed (Guangzhou) Co. Ltd. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacodynamic and Pharmacokinetic of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis [Internet]. clinicaltrials.gov; 2021 Sep [cited 2021 Nov 29]. Report No.: NCT04346888. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04346888"},{"key":"1726_CR168","unstructured":"Immunovant Sciences GmbH. A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients [Internet]. clinicaltrials.gov; 2021 Oct [cited 2021 Nov 29]. Report No.: NCT03863080. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03863080"},{"issue":"5 Pt 1","key":"1726_CR169","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","volume":"6","author":"MD Pescovitz","year":"2006","unstructured":"Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transpl. 2006;6(5 Pt 1):859\u201366.","journal-title":"Am J Transpl"},{"issue":"4","key":"1726_CR170","doi-asserted-by":"publisher","first-page":"131","DOI":"10.18773\/austprescr.2016.053","volume":"39","author":"KL Randall","year":"2016","unstructured":"Randall KL. Rituximab in autoimmune diseases. Aust Prescr. 2016;39(4):131\u20134.","journal-title":"Aust Prescr"},{"issue":"2","key":"1726_CR171","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/1756285609356135","volume":"3","author":"ML Kosmidis","year":"2010","unstructured":"Kosmidis ML, Dalakas MC. Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord. 2010;3(2):93\u2013105.","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"1726_CR172","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","volume":"56","author":"R Tandan","year":"2017","unstructured":"Tandan R, Hehir MK II, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. 2017;56(2):185\u201396.","journal-title":"Muscle Nerve"},{"issue":"4","key":"1726_CR173","doi-asserted-by":"publisher","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","volume":"98","author":"RJ Nowak","year":"2022","unstructured":"Nowak RJ, Coffey CS, Goldstein JM, Dimachkie MM, Benatar M, Kissel JT, et al. Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study. Neurology. 2022;98(4):e376\u201389.","journal-title":"Neurology"},{"issue":"2","key":"1726_CR174","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3233\/JND-180300","volume":"5","author":"O Landon-Cardinal","year":"2018","unstructured":"Landon-Cardinal O, Friedman D, Guiguet M, Lafor\u00eat P, Heming N, Salort-Campana E, et al. Efficacy of Rituximab in refractory generalized anti-AChR myasthenia gravis. J Neuromuscular Dis. 2018;5(2):241\u20139.","journal-title":"J Neuromuscular Dis."},{"issue":"2","key":"1726_CR175","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1750-1172-2-44","volume":"6","author":"VC Juel","year":"2007","unstructured":"Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007;6(2):44.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"1726_CR176","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","volume":"77","author":"S Brauner","year":"2020","unstructured":"Brauner S, Eriksson-Dufva A, Hietala MA, Frisell T, Press R, Piehl F. Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol. 2020;77(8):974\u201381.","journal-title":"JAMA Neurol"},{"issue":"4","key":"1726_CR177","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/jnnp-2019-322606","volume":"91","author":"VD Stefano","year":"2020","unstructured":"Stefano VD, Lupica A, Rispoli MG, Muzio AD, Brighina F, Rodolico C. Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry. 2020;91(4):392\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1726_CR178","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","volume":"11","author":"M Marino","year":"2020","unstructured":"Marino M, Basile U, Spagni G, Napodano C, Iorio R, Gulli F, et al. Long-lasting rituximab-induced reduction of specific\u2014but not total\u2014IgG4 in MuSK-positive myasthenia gravis. Front Immunol. 2020;11:613.","journal-title":"Front Immunol"},{"issue":"10","key":"1726_CR179","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.150051","volume":"42","author":"RF van Vollenhoven","year":"2015","unstructured":"van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol. 2015;42(10):1761\u20136.","journal-title":"J Rheumatol"},{"issue":"2","key":"1726_CR180","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3747\/co.27.6041","volume":"27","author":"D Stewart","year":"2020","unstructured":"Stewart D, Aucoin JS, Crosbie T, Forman M, Lye E, Christofides A, et al. Update on the subcutaneous administration of rituximab in Canadian cancer centres. Curr Oncol. 2020;27(2):113\u20136.","journal-title":"Curr Oncol"},{"key":"1726_CR181","unstructured":"Canada approves rituximab biosimilars Riximyo and Ruxience [Internet]. [cited 2021 Dec 24]. https:\/\/www.gabionline.net\/biosimilars\/news\/Canada-approves-rituximab-biosimilars-Riximyo-and-Ruxience"},{"issue":"3","key":"1726_CR182","doi-asserted-by":"publisher","first-page":"A298","DOI":"10.1016\/j.jval.2015.03.1737","volume":"18","author":"M Georgieva","year":"2015","unstructured":"Georgieva M, Wheeler SJFh Jr. Cost-effectiveness of Rituximab versus Calcineurin inhibitors for refractory Myasthenia Gravis. Value Health. 2015;18(3):A298.","journal-title":"Value Health."},{"issue":"1","key":"1726_CR183","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","volume":"8","author":"FH Du","year":"2017","unstructured":"Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights. 2017;8(1):12.","journal-title":"Auto Immun Highlights."},{"issue":"6","key":"1726_CR184","doi-asserted-by":"publisher","first-page":"E45","DOI":"10.1002\/mus.26707","volume":"60","author":"MJ Waters","year":"2019","unstructured":"Waters MJ, Field D, Ravindran J. Refractory myasthenia gravis successfully treated with ofatumumab. Muscle Nerve. 2019;60(6):E45\u20137.","journal-title":"Muscle Nerve"},{"key":"1726_CR185","first-page":"1","volume":"29","author":"JE Frampton","year":"2020","unstructured":"Frampton JE. Inebilizumab: first approval. Drugs. 2020;29:1\u20136.","journal-title":"Drugs"},{"key":"1726_CR186","unstructured":"Viela Bio. A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study With Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With Myasthenia Gravis [Internet]. clinicaltrials.gov; 2021 Dec [cited 2021 Dec 22]. Report No.: NCT04524273. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04524273"},{"key":"1726_CR187","unstructured":"Novartis Pharmaceuticals. A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Preliminarily Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of CFZ533 in Patients With Moderate to Severe Myasthenia Gravis [Internet]. clinicaltrials.gov; 2020 Dec [cited 2022 Jan 5]. Report No.: NCT02565576. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02565576"},{"key":"1726_CR188","unstructured":"pdf.pdf [Internet]. [cited 2022 Jan 9]. https:\/\/www.novctrd.com\/ctrdweb\/trialresult\/trialresults\/pdf?trialResultId=17276"},{"key":"1726_CR189","unstructured":"PhD PI. Dosing Begins in Phase 2 Trial of Mezagitamab, Antibody to Treat MG [Internet]. [cited 2021 Dec 27]. https:\/\/myastheniagravisnews.com\/news-posts\/2020\/11\/17\/dosing-begins-in-phase-2-trial-of-mezagitamab-antibody-to-treat-mg\/"},{"issue":"16","key":"1726_CR190","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","volume":"90","author":"K Hewett","year":"2018","unstructured":"Hewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ, Bassiri A, et al. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology. 2018;90(16):e1425\u201334.","journal-title":"Neurology"},{"issue":"2","key":"1726_CR191","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/cei.12272","volume":"176","author":"A Uzawa","year":"2014","unstructured":"Uzawa A, Kawaguchi N, Himuro K, Kanai T, Kuwabara S. Serum cytokine and chemokine profiles in patients with myasthenia gravis. Clin Exp Immunol. 2014;176(2):232\u20137.","journal-title":"Clin Exp Immunol"},{"issue":"14","key":"1726_CR192","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s40265-020-01380-2","volume":"80","author":"Y-A Heo","year":"2020","unstructured":"Heo Y-A. Satralizumab: first approval. Drugs. 2020;80(14):1477\u201382.","journal-title":"Drugs"},{"key":"1726_CR193","unstructured":"Hoffmann-La Roche. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis [Internet]. clinicaltrials.gov; 2022 Mar [cited 2022 Apr 3]. Report No.: NCT04963270. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04963270"},{"key":"1726_CR194","doi-asserted-by":"publisher","unstructured":"Estupi\u00f1\u00e1n HY, Bergl\u00f6f A, Zain R, Smith CIE. Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. Front Cell Dev Biol [Internet]. 2021 [cited 2022 Mar 30];0.: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fcell.2021.630942\/full","DOI":"10.3389\/fcell.2021.630942\/full"},{"issue":"9","key":"1726_CR195","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/ITT.S240874","volume":"2","author":"A Lorenzo-Vizcaya","year":"2020","unstructured":"Lorenzo-Vizcaya A, Fasano S, Isenberg DA. Bruton\u2019s Tyrosine kinase inhibitors: a new therapeutic target for the treatment of SLE? Immunotargets Ther. 2020;2(9):105\u201310.","journal-title":"Immunotargets Ther."},{"issue":"9","key":"1726_CR196","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","volume":"20","author":"DS Reich","year":"2021","unstructured":"Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021;20(9):729\u201338.","journal-title":"Lancet Neurol"},{"key":"1726_CR197","unstructured":"Sanofi. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tolebrutinib (SAR442168) in Adults With Generalized Myasthenia Gravis (MG) [Internet]. clinicaltrials.gov; 2022 Feb [cited 2022 Mar 28]. Report No.: NCT05132569. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05132569"},{"issue":"4","key":"1726_CR198","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc2355","volume":"8","author":"SA Rosenberg","year":"2008","unstructured":"Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299\u2013308.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"1726_CR199","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64\u201373.","journal-title":"N Engl J Med"},{"issue":"S1","key":"1726_CR200","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.25418","volume":"94","author":"S Feins","year":"2019","unstructured":"Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3-9.","journal-title":"Am J Hematol"},{"issue":"4","key":"1726_CR201","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):1\u201311.","journal-title":"Blood Cancer J"},{"issue":"5","key":"1726_CR202","doi-asserted-by":"publisher","first-page":"44","DOI":"10.21037\/sci.2018.11.05","volume":"3","author":"J Wang","year":"2018","unstructured":"Wang J, Hu Y, Huang H. Current development of chimeric antigen receptor T-cell therapy. Stem Cell Investig. 2018;3(5):44.","journal-title":"Stem Cell Investig."},{"key":"1726_CR203","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.3389\/fimmu.2020.603237","volume":"11","author":"M Sadeqi Nezhad","year":"2020","unstructured":"Sadeqi Nezhad M, Seifalian A, Bagheri N, Yaghoubi S, Karimi MH, Adbollahpour-Alitappeh M. chimeric antigen receptor based therapy as a potential approach in autoimmune diseases: how close are we to the treatment? Front Immunol. 2020;11:3062.","journal-title":"Front Immunol"},{"issue":"4","key":"1726_CR204","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41423-020-00555-x","volume":"18","author":"J Wei","year":"2021","unstructured":"Wei J, Guo Y, Wang Y, Wu Z, Bo J, Zhang B, et al. Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol. 2021;18(4):792\u2013804.","journal-title":"Cell Mol Immunol"},{"key":"1726_CR205","unstructured":"Cartesian Therapeutics. Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG) [Internet]. clinicaltrials.gov; 2021 Dec [cited 2021 Dec 2]. Report No.: NCT04146051. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04146051"},{"key":"1726_CR206","unstructured":"MS MW. CAR T-cell Therapy Descartes-08 Eased Myasthenia Gravis Symptoms [Internet]. [cited 2021 Dec 4]. https:\/\/myastheniagravisnews.com\/news-posts\/2021\/09\/09\/car-t-cell-therapy-descartes-08-myasthenia-gravis-symptoms\/"},{"key":"1726_CR207","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1200\/EDBK_238691","volume":"39","author":"B Santomasso","year":"2019","unstructured":"Santomasso B, Bachier C, Westin J, Rezvani K, Shpall EJ. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book. 2019;39:433\u201344.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2019","key":"1726_CR208","first-page":"e5727516","volume":"31","author":"Y Chen","year":"2019","unstructured":"Chen Y, Sun J, Liu H, Yin G, Xie Q. Immunotherapy deriving from CAR-T cell treatment in autoimmune diseases. J Immunol Res. 2019;31(2019):e5727516.","journal-title":"J Immunol Res"},{"key":"1726_CR209","doi-asserted-by":"crossref","unstructured":"Oh S, O\u2019Connor K, Payne A. MuSK Chimeric Autoantibody Receptor (CAAR) T Cells for Antigen-specific Cellular Immunotherapy of Myasthenia Gravis (2769). Neurology [Internet]. 2020 Apr 14 [cited 2021 Dec 4];94(15 Supplement). https:\/\/n.neurology.org\/content\/94\/15_Supplement\/2769","DOI":"10.1212\/WNL.94.15_supplement.2769"},{"key":"1726_CR210","unstructured":"Cabaletta Bio. A Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Subjects With Active, Anti-DSG3, Mucosal-dominant Pemphigus Vulgaris [Internet]. clinicaltrials.gov; 2021 Oct [cited 2021 Dec 2]. Report No.: NCT04422912. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04422912"},{"key":"1726_CR211","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.coi.2019.09.005","volume":"61","author":"H-D Chang","year":"2019","unstructured":"Chang H-D, Tokoyoda K, Hoyer B, Alexander T, Khodadadi L, Mei H, et al. Pathogenic memory plasma cells in autoimmunity. Curr Opin Immunol. 2019;61:86\u201391.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"1726_CR212","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/mus.25973","volume":"57","author":"JS Yi","year":"2018","unstructured":"Yi JS, Guptill JT, Stathopoulos P, Nowak RJ, O\u2019Connor KC. B cells in the pathophysiology of myasthenia gravis. Muscle Nerve. 2018;57(2):172\u201384.","journal-title":"Muscle Nerve"},{"issue":"2","key":"1726_CR213","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/bmt.2014.251","volume":"50","author":"T Alexander","year":"2015","unstructured":"Alexander T, Bondanza A, Muraro PA, Greco R, Saccardi R, Daikeler T, et al. SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking. Bone Marrow Transpl. 2015;50(2):173\u201380.","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"1726_CR214","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/archneurol.2009.28","volume":"66","author":"J Strober","year":"2009","unstructured":"Strober J, Cowan MJ, Horn BN. Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis. Arch Neurol. 2009;66(5):659\u201361.","journal-title":"Arch Neurol"},{"issue":"2","key":"1726_CR215","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.nmd.2018.11.008","volume":"29","author":"CL Sossa Melo","year":"2019","unstructured":"Sossa Melo CL, Pe\u00f1a AM, Salazar LA, Jim\u00e9nez SI, G\u00f3mez ED, Chalela CM, et al. Autologous hematopoietic stem cell transplantation in a patient with refractory seropositive myasthenia gravis: a case report. Neuromuscul Disord. 2019;29(2):142\u20135.","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"1726_CR216","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaneurol.2016.0113","volume":"73","author":"A Bryant","year":"2016","unstructured":"Bryant A, Atkins H, Pringle CE, Allan D, Anstee G, Bence-Bruckler I, et al. Myasthenia gravis treated with autologous hematopoietic stem cell transplantation. JAMA Neurol. 2016;73(6):652\u20138.","journal-title":"JAMA Neurol"},{"issue":"11","key":"1726_CR217","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1007\/s00415-020-10010-6","volume":"267","author":"RK Burt","year":"2020","unstructured":"Burt RK, Balabanov R, Tavee J, Han X, Sufit R, Ajroud-Driss S, et al. Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol. 2020;267(11):3378\u201391.","journal-title":"J Neurol"},{"issue":"2","key":"1726_CR218","doi-asserted-by":"publisher","first-page":"234","DOI":"10.7150\/ijms.38363","volume":"17","author":"Z Qin","year":"2020","unstructured":"Qin Z, Huang Q, Zou J, Tang L, Hu Z, Tang X. Progress in hematopoietic stem cell transplantation for CIDP. Int J Med Sci. 2020;17(2):234\u201341.","journal-title":"Int J Med Sci"},{"key":"1726_CR219","unstructured":"Fred Hutchinson Cancer Research Center. High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases [Internet]. clinicaltrials.gov; 2021 Oct [cited 2021 Dec 2]. Report No.: study\/NCT00716066. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00716066"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01726-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01726-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01726-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:08:40Z","timestamp":1744700920000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01726-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":220,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1726"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01726-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"assertion":[{"value":"25 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the publication of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Vera Bril has consulted for Grifols, CSL, UCB, Argenx, Takeda, Alnylam, Octapharma, Pfizer, Powell Mansfield Inc, Akcea, Ionis, Immunovant, Sanofi, Momenta, Roche, Janssen, Alexion, NovoNordisk. She has received research support from Alexion, Grifols, CSL, UCB, Argenx, Takeda, Octapharma, Akcea, Momenta, Immunovant and Ionis. Deepak Menon has nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Deepak Menon: design of work, acquisition, analysis and interpretation of data, drafting the work and revisions. Vera Bril: design of work, drafting the work, analysis of data, revising it critically and final approval of version to be published.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}